Samyang Holdings is an API manufacturer based in South Korea. It holds one active US drug master file and one valid CEP across a filed portfolio of 2 molecules. Its filings concentrate with NPRA (MY) and ARCSA (EC).
| Site | FDA FEI |
|---|---|
| DAEJEON, South Korea | Not on file |
| Gyeonggi-do, South Korea | Not on file |
| Molecule | Regulators | Docs |
|---|---|---|
| Docetaxel | EDQM | 1 |
| Paclitaxel | US FDA | 1 |
Also appears on these molecule pages
| Regulator | Filings | GMP certificates |
|---|---|---|
| NPRA (MY) | 9 | None |
| ARCSA (EC) | 1 | None |
Answered from this company's own record. Where a register holds nothing, the question is not asked rather than answered with a zero. How we count our figures.
Choose your molecules and target markets. Samyang Holdings comes back tiered against every other supplier able to file there.
Start for freeRanked by shared active ingredients where we have them, otherwise by country and comparable credentials.